Is your decision to prescribe empagliflozin for CKD patients without albuminuria influenced by a recent cost-utility analysis showing that empagliflozin was not cost-effective for this group?

Is your decision to prescribe empagliflozin for CKD patients without albuminuria influenced by a recent cost-utility analysis showing that empagliflozin was not cost-effective for this group?

• Yes, I am less likely to prescribe empagliflozin in this group because of cost considerations
• No, I still think the benefit is substantial enough to prescribe empagliflozin for this group
• I do not use SGLT2 inhibitors for patients who have CKD but do not have albuminuria
• Other